Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.51 |
| ▸ | PPARG | P37231 | 7/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | MPC2 | O95563 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974989 | 0.90 | PPARG (0.56) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL8975130 | 0.90 | FFAR1 (0.52) | FFAR1PPARGPPARA | |
| SCHEMBL8406934 | 0.85 | PPARG (0.63) | FFAR1PPARGCYP2C9 | |
| SCHEMBL8305440 | 0.85 | PPARG (0.63) | FFAR1PPARGCYP2C9 | |
| SCHEMBL8305245 | 0.85 | PPARG (0.63) | FFAR1PPARGCYP2C9 | |
| SCHEMBL8305247 | 0.85 | PPARG (0.63) | FFAR1PPARGCYP2C9 | |
| SCHEMBL8974677 | 0.83 | PPARG (0.57) | FFAR1PPARGPPARAMPC2CYP2C8 | |
| SCHEMBL8974550 | 0.83 | FFAR1 (0.52) | FFAR1PPARG | |
| SCHEMBL8975029 | 0.82 | FFAR1 (0.50) | FFAR1PPARG | |
| SCHEMBL8974649 | 0.82 | FFAR1 (0.53) | FFAR1PPARGPPARAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |